Press

Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Drug Candidates

Oct 4 • 4 min read

The Psybrary™ portfolio includes numerous unique, previously unreported molecules, which are protected by Enveric’s expansive and growing intellectual property estate Enveric Biosciences (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has reached a milestone in its…

Atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

Oct 3 • 3 min read

Atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the completion of the Phase 1 study of VLS-01 in healthy participants. “We are pleased to report the completion of the Phase 1 study of VLS-01, in which we demonstrated a supportive PK/PD profile of our proprietary…

Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder

Oct 3 • 4 min read

–Topline efficacy data expected in Q4 2023 – – Preparations are underway to scale the CYB003 program to a potential Phase 3 study in early 2024 – Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced the…

The Future of Psychedelic Access in Canada: PsyCan Releases White Paper Reviewing Regulatory Options for Psychedelics

Oct 3 • 4 min read

PsyCan — the not-for-profit trade association of legally-operating Canadian psychedelic companies — is pleased to share its 2023 White Paper on the future of psychedelic access in Canada: Beyond the Special Access Program — Regulatory Analysis and Recommendations on Psychedelic Access in Canada. The White Paper is accessible here: https://psychedelicscanada.org/whitepaper. The White Paper examines regulatory reforms governing access to psychedelics….

Sunstone Therapies Announces Expansion of Innovative Dyad Study

Oct 3 • 3 min read

Sunstone Therapies Announces Expansion of Innovative Dyad Study Sunstone Therapies, a leader in the delivery of psychedelic-assisted therapy in the medical setting and the development and execution of clinical trials, today announces the expansion of its MDMA-assisted Dyad Study to include 20 dyads (pairs of participants). The study is being funded in part from a significant grant by…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427